Novo Nordisk Reports Q2 Revenue Decline Amid Falling Diabetes Drug Prices

Recently,Novo NordiskNovo Nordisk Announces Q2 2018 Financial Results. Affected by factors such as stalled growth in the diabetes market, Novo Nordisk’s revenue declined by 4% in the second quarter, but performance of its key brands remained robust.

Although total sales fell to $4.3 billion, profits rose 4% to $1.6 billion. The company’s glucose-lowering drugsVictozaup 6% to $888 million,Xultrohpyincreased by 154% to $112 million,SaxendaRising 40% to $138 million for non-insulin drugsOzempicSales performance has also improved, generating $41 million in the North American region during the first half of this year.

ButDiabetes Market Segmentsales fell 4% to $3.5 million. The company stated that the North America regionTresiba and Levemirsales decreased by 4% and 10%, respectively.

Novo Nordisk stated that this year's operating profit growth rate would be revised downward from the previously expected 9% to 7%, with the operating profit itself increasing by 2%-5%. However, the company still expects the sales growth rate to reach between 3%-5%. In addition,Novo NordiskIt also stated that, after reviewing its drug combination for obese patients, the drugFGF-21Phase I development will no longer proceed. It is reported that the decision to terminate the trial was not due to any major safety issues with the drug, but rather because the company will further advance the clinical development of the drug in other serious chronic diseases.

Analysts believe that, affected by price pressures, Novo Nordisk next yearBasal Insulin PricePrices are expected to decline further, but investors need not be overly concerned. The number of competitors in the insulin market continues to rise, with product categories expanding from two to five, and intensifying competition is forcing continuous price reductions.

Novo Nordisk’s CEO is optimistic about this. He stated that the company should be able to leverage its marketing channels and mitigate the impact of price declines on its profits through measures such as insurance reimbursement.

On the other hand, due to a series of recent adjustments by Novo Nordisk, analysts seem uncertain about its future development trajectory.

Since its formation in 1989 through the merger of Novo Laboratories and Nordisk Insulin Laboratory, Novo Nordisk has played a pivotal role in the development and licensing of blockbuster drugs in the diabetes field, as well as in the treatment of major diseases. After years of refinement, it has become a global leader in insulin production and diabetes care. In 2015 alone, its sales of glucose-lowering medications reached $12 billion, with a thriving product portfolio that far surpassed other companies in the diabetes sector, leading the diabetes drug market. In recent years, Novo Nordisk has been engaged in fierce competition with its rivals. However, in 2016, the company announced plans to lay off approximately 1,000 employees to help cut costs. The layoffs spanned research and development, sales, and administrative departments, with about half of the affected employees based in Denmark. Recent reports indicate that the company will conduct another round of layoffs on a similar scale.

HoweverNovo Nordisk alsoActively advancingGLP-1 Hypoglycemic DrugssemaglutideThis new drug eliminates the inconvenience of subcutaneous injections required by previous medications. Furthermore, although Victoza and Ozempic have been on the market for many years, they have remained popular due to their outstanding efficacy since their launch. Novo Nordisk believes that the introduction of this new drug will help drive a 3%-5% increase in sales.

In recent years, relying onInsulin-based Hypoglycemic AgentsNovo Nordisk, a leader in the field of diabetes treatment, has launched two blockbuster GLP-1 receptor agonists, liraglutide and semaglutide, in response to market pressure from other GLP-1 and DPP-4i drugs. This strategic move has solidified its position as the top player in the GLP-1 sector and gradually widened the gap with competitors such as Sanofi and Eli Lilly. Analysts believe that despite competition in the diabetes businessIntense, but Novo Nordisk will remain the dominant player in this market over the next five years.(Compiled by Sina Medicine/Fan Dongdong)

Sources for articles and images:

1、Novo CEO: Expect U.S. diabetes drug prices to continue their downward spiral next year

2、Novo Nordisk sees revenues drop in Q2